SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence
Background. Over the last few years, the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) has increased substantially in medical practice due to their documented benefits in cardiorenal and metabolic health. In this sense, and in addit...
Saved in:
Main Authors: | , , , , , , , , , |
---|---|
Format: | article |
Language: | EN |
Published: |
Hindawi Limited
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/2429d38f9c04442fa80e1693aa5bb47e |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|